Direct to Consumer (DTC) advertising of prescription drugs
is the subject of an ongoing debate among health officials
over the relative merits, and the advertising of gene related
products and services are an even greater potential concern.
Direct marketing could include advertisements for drugs and
testing procedures that have previously been available only
through licensed medical providers. With the growth of so-called
“storefront clinics” a patient can get XRays,
MRI’s, blood tests and genetic testing services on a
walk-in, pay as you go basis.
Some health professionals, including genetic counselors,
believe that the direct marketing of genetic screening tests
to the public may lead to disappointment and perhaps harm.
A major concern among these professionals is that there is
a complex set of facts that may not be clear to potential
consumers.
The benefits and liabilities may not be presented openly and
counseling on the range of potential outcomes and consequences
is not available. Just as the perceived risk of an
airline crash is greater after a widely publicized accident,
a person’s perceived value of a genetic screen may be
greater after a relative’s diagnosis and a DTC advertisement
on the disease genes.
Importantly, there is currently no Federal or State regulatory
agency responsible for evaluating the DTC advertising of genetic
services. In contrast, federal law requires that drug companies
can only advertise drugs that have received FDA approval and
the list of possible side effects must be included.
Currently there exist about 28 different tests that can show
your genetic predisposition. A list of them is available here.
|